Agilent Showcases Advances in Precision Oncology and Digital Pathology at USCAP 2026

Key Terms

precision oncology medical

Precision oncology uses detailed biological information from a patient’s tumor—like genetic changes or specific markers—to choose treatments most likely to work for that individual, much like tailoring a suit to a person’s measurements instead of selling one-size-fits-all clothing. It matters to investors because these targeted approaches can improve treatment success, support premium pricing and companion diagnostic tests, and shorten development and approval timelines, creating focused markets with both higher potential returns and specialized risks.

digital pathology medical

Digital pathology is the process of converting traditional microscope slides into high-resolution digital images and using software, cloud systems, and sometimes AI to view, analyze, store and share those images. It matters to investors because it can speed diagnosis, enable remote consultations, reduce laboratory bottlenecks and create software-driven services and recurring revenue—like the shift from film to digital photography, unlocking scale, efficiency and new monetization opportunities in healthcare.

pd‑l1 medical

PD‑L1 is a protein found on the surface of some cells that can tell the immune system to slow down or ignore those cells—think of it as a cellular 'off switch' that reduces immune attack. It matters to investors because drugs that block PD‑L1 can unleash the immune system to fight cancer, and levels of PD‑L1 are used as a biomarker to predict which patients may benefit, affecting drug development, approvals, and market potential.

epithelial ovarian, fallopian tube, or primary peritoneal carcinoma medical

A group of related cancers that arise from the surface cells of the ovary, the lining of the fallopian tube, or the membrane covering the abdominal organs; they behave similarly and are often treated the same way. For investors, these diagnoses matter because they define the market for drugs, diagnostics, and devices aimed at detection, treatment, or monitoring—think of it as one market segment served by therapies that can apply across these closely linked cancer types.

biomarker medical

A biomarker is a measurable indicator found in the body, such as in blood or tissues, that provides information about health, disease, or how the body responds to treatment. For investors, biomarkers can signal the potential success or risk of medical products or therapies, influencing the value of related companies and industry trends. They act like signals or clues that help assess the progress of medical advancements and their market impact.

dako omnis technical

An automated laboratory instrument that prepares and stains tissue samples so pathologists can see specific disease markers under a microscope. Like a high-end kitchen appliance that cooks the same recipe precisely every time, it speeds up testing, reduces human error and enables standardized diagnostic checks that doctors use to choose treatments. Investors care because widespread use can drive demand for related diagnostic tests, support faster approval and uptake of targeted therapies, and create recurring revenue from consumables and service contracts.

ihc medical

Immunohistochemistry (IHC) is a laboratory technique that uses labeled antibodies to detect and visually highlight specific proteins inside tissue samples, producing stained patterns pathologists can see under a microscope. For investors, IHC matters because it helps confirm whether a drug or diagnostic hits the intended target in real patient tissues and can support patient selection, clinical trial design and regulatory filings — essentially acting like a map that shows where a therapy is likely to work and reducing clinical and regulatory risk.

companion diagnostics medical

A companion diagnostic is a medical test used alongside a specific drug or therapy to identify which patients are likely to benefit from it or may face safety risks. Think of it as a tailored matchmaker that tells doctors whether a particular treatment is a good fit for an individual. For investors, these tests matter because they can shape a drug’s approved use, speed and cost of development, patient uptake, reimbursement, and the commercial value of both the therapy and the diagnostic.

Expanded PD‑L1 indication and end‑to‑end digital pathology workflows support modern pathology practice

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) today announced it will feature its latest advances in precision oncology and digital pathology workflows at the 2026 United States and Canadian Academy of Pathology (USCAP) Annual Meeting, taking place March 21-26 in San Antonio, Texas. Agilent will highlight expanded biomarker testing capabilities, continued progress in digital pathology adoption, and the evolving role of the Dako Omnis family of instruments as a foundation for scalable, automation‑ready pathology laboratories.

At USCAP 2026, Agilent will feature its continued expansion in oncology diagnostics, including a new PD‑L1 indication for epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC), reinforcing Agilent’s commitment to supporting biomarker‑driven precision oncology. This addition builds on Agilent’s established PD‑L1 portfolio and supports laboratories as testing needs evolve alongside increasingly complex therapeutic landscapes.

Agilent will also demonstrate its progress in advancing end‑to‑end digital pathology workflows, designed to help laboratories improve efficiency, reproducibility, and confidence while scaling for future demand. These workflows integrate staining, imaging, and data management to support streamlined slide digitization, organization, and helping pathology teams manage work from slide preparation through digital image capture and case review.

“USCAP is a critical forum for sharing meaningful advances in pathology that directly impact patient care,” said Majken Nielsen, vice president of Clinical Businesses and head of CDD Product Management at Agilent. “Our continued investment in precision oncology biomarkers, digital pathology, and scalable platforms like the Dako Omnis family of instruments reflects Agilent’s commitment to helping laboratories navigate increasing complexity while delivering confident, reproducible results.”

Throughout the meeting, Agilent will collaborate with members of the digital pathology ecosystem, including Hamamatsu, Proscia, PathAI, and Visiopharm, demonstrating interoperable solutions that support open, flexible adoption of digital pathology technologies. These collaborations reinforce Agilent’s role as a trusted provider of integrated pathology solutions.

Conference attendees can visit Agilent at booth #123. Agilent will also host and participate in educational and networking events during USCAP 2026, including:

• Digital Pathology Symposium: “Future Ready Total Pathology Workflows: Integrating Advanced Staining and Digital Solutions in Today’s Practice” — Monday, March 23, 2026, 12:00-1:00 p.m., Seminar Room 7, featuring “The Intersection of Pathology and Digital Workflows,” presented by Dr. Doug Clark, Agilent associate vice president and pathologist, and “The ROI Case for Implementing Digital Pathology/Realized Benefits Mid Adoption,” presented by Melonie Falcon, CEO, Delta Pathology.
• “Gastric Cancer and PD‑L1 Expression: Morphology, Biomarker Landscape, and Case Analysis” — Tuesday, March 24, 2026, 12:00-1:00 p.m., Seminar Room 2, presented by Dr. Deborah Jue, Dr. Mar Iglesias Comma, and Dr. Ashish Mogal.
• “PD‑L1 in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC): Scoring for a Newly Established Indication” — Wednesday, March 25, 2026, 12:00-1:00 p.m., Seminar Room 2, presented by Dr. Marie Smithgall, assistant professor, Columbia University Irving Medical Center.

Agilent’s presence at USCAP 2026 underscores its strategy to expand from a strong foundation in staining, IHC, ISH, and companion diagnostics into fully integrated, digital‑enabled pathology workflows. By combining trusted reagents, scalable platforms, and ecosystem partnerships, Agilent continues to support laboratories as they transition toward more connected, data‑driven pathology environments. Agilent is committed to being the premier lab partner for a better world, empowering pathologists with innovative, reliable solutions that support confident diagnoses and improved patient outcomes.

About Agilent Technologies

Agilent Technologies, Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers’ most challenging questions. The company generated revenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260319962666/en/

MEDIA CONTACT:

Kate Coyle

Agilent Technologies Inc.

+1 302-633-7490

kate.coyle@agilent.com

Source: Agilent Technologies Inc.